16 Nov 2023 • In a milestone move, the U.S. Food and Drug Administration approves the first-ever vaccine for chikungunya. Designed for individuals aged 18 and above at heightened risk of chikungunya exposure, Ixchiq stands out as a single-dose injection.

The effectiveness of Ixchiq is based on immune response data from a clinical study conducted in the United States in individuals 18 years of age and older. Ixchiq is administered as a single dose by injection into the muscle. It contains a live, weakened version of the chikungunya virus and may cause symptoms in the vaccine recipient similar to those experienced by people who have chikungunya disease.

The FDA is requiring the company to conduct a postmarketing study to assess the serious risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

Source: FDA | Read full story